A szkizofrénia diagnózisa Bleulerto{double acute}l a DSM-V-ig

Translated title of the contribution: From Bleuler to DSM-V: Diagnosing schizophrenia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The diagnosis of schizophrenia has undergone substantial change during the last 100 years since its first descriptions by Kraepelin and Bleuler, this process is still continuing at present. The never ending changes of the diagnosis are partially attributable to the symptomatologic heterogeneity seen in schizophrenia and the complex etiology understood only to a small extent. On the other hand, the evolution of the diagnostic systems reflects the standpoints, priorities, and possibilities in the treatment of the disorder in the given period of time. The original accounts of Kraepelin and Bleuler grasped distinct features of schizophrenia, these works still influence our understanding and concepts about the disorder. To resolve the problem of phenotypic heterogeneity there have been two conceptual approaches appearing throughout the history of schizophrenia diagnostics. The categorical approach has defined subgroups within the disorder, whereas dimensional thinking puts emphasis on the severity of different symptom clusters. The present revision of the DSM is characterized by the strengthening of the dimensional approach. Ongoing and future research about pathophysiologically determined biomarkers will have a major impact on the diagnostic system of schizophrenia. The overall aim of these changes is to improve our understanding and indirectly the treatment possibilities of patients suffering from this complex disorder.

Original languageHungarian
Pages (from-to)193-203
Number of pages11
JournalNeuropsychopharmacologia Hungarica
Volume13
Issue number4
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Diagnostic and Statistical Manual of Mental Disorders
Schizophrenia
Biomarkers
History
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

A szkizofrénia diagnózisa Bleulerto{double acute}l a DSM-V-ig. / Réthelyi, J.

In: Neuropsychopharmacologia Hungarica, Vol. 13, No. 4, 12.2011, p. 193-203.

Research output: Contribution to journalArticle

@article{a46dfbc9eb544e5aa6de286f7aa26c7b,
title = "A szkizofr{\'e}nia diagn{\'o}zisa Bleulerto{double acute}l a DSM-V-ig",
abstract = "The diagnosis of schizophrenia has undergone substantial change during the last 100 years since its first descriptions by Kraepelin and Bleuler, this process is still continuing at present. The never ending changes of the diagnosis are partially attributable to the symptomatologic heterogeneity seen in schizophrenia and the complex etiology understood only to a small extent. On the other hand, the evolution of the diagnostic systems reflects the standpoints, priorities, and possibilities in the treatment of the disorder in the given period of time. The original accounts of Kraepelin and Bleuler grasped distinct features of schizophrenia, these works still influence our understanding and concepts about the disorder. To resolve the problem of phenotypic heterogeneity there have been two conceptual approaches appearing throughout the history of schizophrenia diagnostics. The categorical approach has defined subgroups within the disorder, whereas dimensional thinking puts emphasis on the severity of different symptom clusters. The present revision of the DSM is characterized by the strengthening of the dimensional approach. Ongoing and future research about pathophysiologically determined biomarkers will have a major impact on the diagnostic system of schizophrenia. The overall aim of these changes is to improve our understanding and indirectly the treatment possibilities of patients suffering from this complex disorder.",
keywords = "Biomarker, Bleuler, Categorical, Diagnosis, Dimensional, DSM-V, Kraepelin, Schizophrenia",
author = "J. R{\'e}thelyi",
year = "2011",
month = "12",
doi = "10.5706/nph201112002",
language = "Hungarian",
volume = "13",
pages = "193--203",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "4",

}

TY - JOUR

T1 - A szkizofrénia diagnózisa Bleulerto{double acute}l a DSM-V-ig

AU - Réthelyi, J.

PY - 2011/12

Y1 - 2011/12

N2 - The diagnosis of schizophrenia has undergone substantial change during the last 100 years since its first descriptions by Kraepelin and Bleuler, this process is still continuing at present. The never ending changes of the diagnosis are partially attributable to the symptomatologic heterogeneity seen in schizophrenia and the complex etiology understood only to a small extent. On the other hand, the evolution of the diagnostic systems reflects the standpoints, priorities, and possibilities in the treatment of the disorder in the given period of time. The original accounts of Kraepelin and Bleuler grasped distinct features of schizophrenia, these works still influence our understanding and concepts about the disorder. To resolve the problem of phenotypic heterogeneity there have been two conceptual approaches appearing throughout the history of schizophrenia diagnostics. The categorical approach has defined subgroups within the disorder, whereas dimensional thinking puts emphasis on the severity of different symptom clusters. The present revision of the DSM is characterized by the strengthening of the dimensional approach. Ongoing and future research about pathophysiologically determined biomarkers will have a major impact on the diagnostic system of schizophrenia. The overall aim of these changes is to improve our understanding and indirectly the treatment possibilities of patients suffering from this complex disorder.

AB - The diagnosis of schizophrenia has undergone substantial change during the last 100 years since its first descriptions by Kraepelin and Bleuler, this process is still continuing at present. The never ending changes of the diagnosis are partially attributable to the symptomatologic heterogeneity seen in schizophrenia and the complex etiology understood only to a small extent. On the other hand, the evolution of the diagnostic systems reflects the standpoints, priorities, and possibilities in the treatment of the disorder in the given period of time. The original accounts of Kraepelin and Bleuler grasped distinct features of schizophrenia, these works still influence our understanding and concepts about the disorder. To resolve the problem of phenotypic heterogeneity there have been two conceptual approaches appearing throughout the history of schizophrenia diagnostics. The categorical approach has defined subgroups within the disorder, whereas dimensional thinking puts emphasis on the severity of different symptom clusters. The present revision of the DSM is characterized by the strengthening of the dimensional approach. Ongoing and future research about pathophysiologically determined biomarkers will have a major impact on the diagnostic system of schizophrenia. The overall aim of these changes is to improve our understanding and indirectly the treatment possibilities of patients suffering from this complex disorder.

KW - Biomarker

KW - Bleuler

KW - Categorical

KW - Diagnosis

KW - Dimensional

KW - DSM-V

KW - Kraepelin

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84858256624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858256624&partnerID=8YFLogxK

U2 - 10.5706/nph201112002

DO - 10.5706/nph201112002

M3 - Article

C2 - 22184187

AN - SCOPUS:84858256624

VL - 13

SP - 193

EP - 203

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 4

ER -